C-type natriuretic peptide (1-22) (human, rat, swine)Endogenous peptide agonist at NPR2 CAS# 127869-51-6 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 127869-51-6 | SDF | Download SDF |
PubChem ID | 16179407 | Appearance | Powder |
Formula | C93H157N27O28S3 | M.Wt | 2197.61 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: 3. Recommended solution: | ||
Sequence | GLSKGCFGLKLDRIGSMSGLGC (Modifications: Disulfide bridge between 6 - 22) | ||
SMILES | CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CN)C(=O)O)CC(C)C)CO)CCSC)CO | ||
Standard InChIKey | UHSBKBYWHCBDCJ-DYGWFTAGSA-N | ||
Standard InChI | InChI=1S/C93H157N27O28S3/c1-12-52(10)76-91(146)104-42-72(127)108-65(44-122)88(143)114-57(26-30-149-11)82(137)118-64(43-121)80(135)103-39-70(125)106-58(31-48(2)3)78(133)101-41-74(129)110-68(92(147)148)47-151-150-46-67(109-73(128)40-100-77(132)54(23-16-18-27-94)111-89(144)66(45-123)119-85(140)59(32-49(4)5)105-69(124)37-96)90(145)116-62(35-53-21-14-13-15-22-53)79(134)102-38-71(126)107-60(33-50(6)7)84(139)112-55(24-17-19-28-95)81(136)115-61(34-51(8)9)86(141)117-63(36-75(130)131)87(142)113-56(83(138)120-76)25-20-29-99-93(97)98/h13-15,21-22,48-52,54-68,76,121-123H,12,16-20,23-47,94-96H2,1-11H3,(H,100,132)(H,101,133)(H,102,134)(H,103,135)(H,104,146)(H,105,124)(H,106,125)(H,107,126)(H,108,127)(H,109,128)(H,110,129)(H,111,144)(H,112,139)(H,113,142)(H,114,143)(H,115,136)(H,116,145)(H,117,141)(H,118,137)(H,119,140)(H,120,138)(H,130,131)(H,147,148)(H4,97,98,99)/t52-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Endogenous peptide found in plasma and cerebrospinal fluid. Behaves as an agonist at natriuretic peptide receptor NPR2 (NPRB) and exhibits affinity for NPR3 (NPRC). Inhibits L-type calcium currents in myocytes and exhibits antiproliferative effects in cardiac fibroblasts in vitro. Regulates cartilage homeostasis, body fluid volume and exhibits vasodilatory activity in vivo. |
C-type natriuretic peptide (1-22) (human, rat, swine) Dilution Calculator
C-type natriuretic peptide (1-22) (human, rat, swine) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Saquinavir
Catalog No.:BCC1921
CAS No.:127779-20-8
- Dryocrassin ABBA
Catalog No.:BCN6276
CAS No.:12777-70-7
- 2'-O-Methylbroussonin A
Catalog No.:BCN7318
CAS No.:127757-13-5
- SKF 97541
Catalog No.:BCC6626
CAS No.:127729-35-5
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- (2R)-5,7-Dimethoxyflavanone
Catalog No.:BCN7806
CAS No.:1277188-85-8
- 9alpha,11-Dihydroxydrim-7-en-6-one
Catalog No.:BCN7225
CAS No.:127681-58-7
- PF-4989216
Catalog No.:BCC6468
CAS No.:1276553-09-3
- Cadherin Peptide, avian
Catalog No.:BCC1018
CAS No.:127650-08-2
- Oleficin
Catalog No.:BCN1848
CAS No.:12764-54-4
- Fananserin
Catalog No.:BCC7440
CAS No.:127625-29-0
- PF-3644022
Catalog No.:BCC6136
CAS No.:1276121-88-0
- CGP 37849
Catalog No.:BCC7078
CAS No.:127910-31-0
- CGP 39551
Catalog No.:BCC7053
CAS No.:127910-32-1
- 24(31)-Dehydrocarboxyacetylquercinic acid
Catalog No.:BCN1589
CAS No.:127970-62-1
- CU CPT 4a
Catalog No.:BCC6319
CAS No.:1279713-77-7
- Teucrin A
Catalog No.:BCC8259
CAS No.:12798-51-5
- Ursodiol
Catalog No.:BCC4945
CAS No.:128-13-2
- Pregnanolone
Catalog No.:BCC7736
CAS No.:128-20-1
- Sennoside B
Catalog No.:BCN1003
CAS No.:128-57-4
- Arvanil
Catalog No.:BCC7026
CAS No.:128007-31-8
- erythro-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1588
CAS No.:1280602-81-4
- Fmoc-D-Ser(tBu)-OH
Catalog No.:BCC3548
CAS No.:128107-47-1
- Escitalopram
Catalog No.:BCC4193
CAS No.:128196-01-0
Natriuretic peptide C receptor signalling in the heart and vasculature.[Pubmed:18006579]
J Physiol. 2008 Jan 15;586(2):353-66.
Natriuretic peptides (NPs), including atrial, brain and C-type natriuretic peptides (ANP, BNP and CNP), bind two classes of cell surface receptors: the guanylyl cyclase-linked A and B receptors (NPR-A and NPR-B) and the C receptor (NPR-C). The biological effects of NPs have been mainly attributed to changes in intracellular cGMP following their binding to NPR-A and NPR-B. NPR-C does not include a guanylyl cyclase domain. It has been denoted as a clearance receptor and is thought to bind and internalize NPs for ultimate degradation. However, a substantial body of biochemical work has demonstrated the ability of NPR-C to couple to inhibitory G proteins (Gi) and cause inhibition of adenylyl cyclase and activation of phospholipase-C. Recently, novel physiological effects of NPs, mediated specifically by NPR-C, have been discovered in the heart and vasculature. We have described the ability of CNP, acting via NPR-C, to selectively inhibit L-type calcium currents in atrial and ventricular myocytes, as well as in pacemaker cells (sinoatrial node myocytes). In contrast, our studies of the electrophysiological effects of CNP on cardiac fibroblasts demonstrated an NPR-C-Gi-phospholipase-C-dependent activation of a non-selective cation current mediated by transient receptor potential (TRP) channels. It is also known that CNP and BNP have important anti-proliferative effects in cardiac fibroblasts that appear to involve NPR-C. In the mammalian resistance vessels, including mesenteric and coronary arteries, CNP has been found to function as an NPR-C-dependent endothelium-derived hyperpolarizing factor that regulates local blood flow and systemic blood pressure by hyperpolarizing smooth muscle cells. In this review we highlight the role of NPR-C in mediating these NP effects in myocytes and fibroblasts from the heart as well as in vascular smooth muscle cells.
C-natriuretic peptide: an important regulator of cartilage.[Pubmed:17681481]
Mol Genet Metab. 2007 Nov;92(3):210-5.
Over the past several years, the C-natriuretic peptide (CNP) has emerged as an important regulator of cartilage homeostasis and endochondral bone growth. In mice, genetic ablation of CNP or its cognate receptor NPRB results in marked dwarfism. When a downstream component of CNP signaling, protein kinase-G II (PKGII), is removed from cartilage, the mice have disturbed chondrocyte proliferation and cartilage matrix production. In contrast, activating mutations in PKGII as well as overexpression of CNP result in significant skeletal overgrowth in mice, demonstrating the positive role of CNP signaling in regulation of mammalian chondrocyte proliferation and cartilage matrix production. This is further supported by the existence of a human dwarfism, acromesomelic dysplasia Maroteaux-type (MIM #602875) that is caused by loss-of-function of NPRB. In comparison with other signaling systems, the molecular basis of CNP signaling in cartilage remains largely unknown, thus leaving many important questions open for future investigation. This review summarizes our current knowledge about the mechanism of CNP signaling in cartilage, areas for future investigation and its potential therapeutic uses.
Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.[Pubmed:1309330]
Endocrinology. 1992 Jan;130(1):229-39.
To elucidate the ligand-receptor relationship of the natriuretic peptide system, which comprises at least three endogenous ligands, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), and three receptors, the ANP-A receptor or guanylate cyclase-A (GC-A), the ANP-B receptor or guanylate cyclase-B (GC-B), and the clearance receptor (C-receptor), we characterized the receptor preparations from human, bovine, and rat tissues and cultured cells with the aid of the binding assay, Northern blot technique, and the cGMP production method. Using these receptor preparations, we examined the binding affinities of ANP, BNP, and CNP for the C-receptor and their potencies for cGMP production via the ANP-A receptor (GC-A) and the ANP-B receptor (GC-B). These analyses revealed the presence of a marked species difference in the receptor selectivity of the natriuretic peptide family, especially among BNPs. Therefore, we investigated the receptor selectivity of the natriuretic peptide family using the homologous assay system with endogenous ligands and receptors of the same species. The rank order of binding affinity for the C-receptor was ANP greater than CNP greater than BNP in both humans and rats. The rank order of potency for cGMP production via the ANP-A receptor (GC-A) was ANP greater than or equal to BNP much greater than CNP, but that via the ANP-B receptor (GC-B) was CNP greater than ANP greater than or equal to BNP. These findings on the receptor selectivity of the natriuretic peptide family provide a new insight into the understanding of the physiological and clinical implications of the natriuretic peptide system.